BACKGROUND & AIMS: Inflammatory bowel disease (IBD) refers to 2 chronic inflammatory diseases of the intestine, ie, ulcerative colitis and Crohn's disease. IBD results from environmental factors (eg, bacterial antigens) triggering a dysregulated immune response in genetically predisposed hosts. Although the basis of IBD is incompletely understood, a number of recent studies have implicated defective innate immune responses in the pathogenesis of IBD. In this regard, there is much interest in therapies that activate innate immunity (eg, recombinant granulocyte-macrophage colony-stimulating factor). METHODS: In this study, we screened expression and function of circulating leukocyte granulocyte-macrophage colony-stimulating factor receptor (CD116) messenger RNA and surface protein in 52 IBD patients and 52 healthy controls. RESULTS: Our results show that both granulocyte and monocyte CD116 levels, but not CD114 or interleukin-3Rα, were significantly decreased in IBD compared to control (P<.001) and disease controls (irritable bowel syndrome; P<.001; rheumatoid arthritis; P<.025). IBD-associated CD116 repression was more prominent in patients with ulcerative colitis compared to Crohn's disease (P<.05), was independent of disease activity (P>.05), and was not influenced by current medications (P>.05). Receiver operating characteristic curve analysis revealed that leukocyte CD116 expression is a sensitive (85%) and specific (92%) biomarker for IBD. Moreover, granulocyte CD116-mediated function (phosphorylation of signal transducers and activators of transcription 3) paralleled decreased expression of CD116 in IBD granulocytes compared to control (P<.001). CONCLUSIONS: These studies identify defective expression and function of CD116 as a distinguishing feature of IBD and implicate an associated defect in innate immune responses toward granulocyte-macrophage colony-stimulating factor.
BACKGROUND & AIMS:Inflammatory bowel disease (IBD) refers to 2 chronic inflammatory diseases of the intestine, ie, ulcerative colitis and Crohn's disease. IBD results from environmental factors (eg, bacterial antigens) triggering a dysregulated immune response in genetically predisposed hosts. Although the basis of IBD is incompletely understood, a number of recent studies have implicated defective innate immune responses in the pathogenesis of IBD. In this regard, there is much interest in therapies that activate innate immunity (eg, recombinant granulocyte-macrophage colony-stimulating factor). METHODS: In this study, we screened expression and function of circulating leukocyte granulocyte-macrophage colony-stimulating factor receptor (CD116) messenger RNA and surface protein in 52 IBD patients and 52 healthy controls. RESULTS: Our results show that both granulocyte and monocyte CD116 levels, but not CD114 or interleukin-3Rα, were significantly decreased in IBD compared to control (P<.001) and disease controls (irritable bowel syndrome; P<.001; rheumatoid arthritis; P<.025). IBD-associated CD116 repression was more prominent in patients with ulcerative colitis compared to Crohn's disease (P<.05), was independent of disease activity (P>.05), and was not influenced by current medications (P>.05). Receiver operating characteristic curve analysis revealed that leukocyte CD116 expression is a sensitive (85%) and specific (92%) biomarker for IBD. Moreover, granulocyte CD116-mediated function (phosphorylation of signal transducers and activators of transcription 3) paralleled decreased expression of CD116 in IBD granulocytes compared to control (P<.001). CONCLUSIONS: These studies identify defective expression and function of CD116 as a distinguishing feature of IBD and implicate an associated defect in innate immune responses toward granulocyte-macrophage colony-stimulating factor.
Authors: Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovský; Frederick Wolfe; Gillian Hawker Journal: Arthritis Rheum Date: 2010-09
Authors: Xiaonan Han; Kanji Uchida; Ingrid Jurickova; Diana Koch; Tara Willson; Charles Samson; Erin Bonkowski; Anna Trauernicht; Mi-Ok Kim; Gitit Tomer; Marla Dubinsky; Scott Plevy; Subra Kugathsan; Bruce C Trapnell; Lee A Denson Journal: Gastroenterology Date: 2008-12-24 Impact factor: 22.682
Authors: F Stephen Hodi; Sandra Lee; David F McDermott; Uma N Rao; Lisa H Butterfield; Ahmad A Tarhini; Philip Leming; Igor Puzanov; Donghoon Shin; John M Kirkwood Journal: JAMA Date: 2014-11-05 Impact factor: 56.272
Authors: Chao Li; Robert S Flynn; John R Grider; Karnam S Murthy; John M Kellum; Homayoon Akbari; John F Kuemmerle Journal: Inflamm Bowel Dis Date: 2013-12 Impact factor: 5.325
Authors: Laia Egea; Christopher S McAllister; Omar Lakhdari; Ivelina Minev; Steve Shenouda; Martin F Kagnoff Journal: J Immunol Date: 2013-01-16 Impact factor: 5.422
Authors: I Jurickova; M H Collins; C Chalk; A Seese; R Bezold; K Lake; D von Allmen; J S Frischer; R A Falcone; B C Trapnell; L A Denson Journal: Clin Exp Immunol Date: 2013-06 Impact factor: 4.330
Authors: Ling-Shiang Chuang; Nicole Villaverde; Ken Y Hui; Arthur Mortha; Adeeb Rahman; Adam P Levine; Talin Haritunians; Sok Meng Evelyn Ng; Wei Zhang; Nai-Yun Hsu; Jody-Ann Facey; Tramy Luong; Heriberto Fernandez-Hernandez; Dalin Li; Manuel Rivas; Elena R Schiff; Alexander Gusev; L Phillip Schumm; Beatrice M Bowen; Yashoda Sharma; Kaida Ning; Romain Remark; Sacha Gnjatic; Peter Legnani; James George; Bruce E Sands; Joanne M Stempak; Lisa W Datta; Seth Lipka; Seymour Katz; Adam S Cheifetz; Nir Barzilai; Nikolas Pontikos; Clara Abraham; Marla J Dubinsky; Stephan Targan; Kent Taylor; Jerome I Rotter; Ellen J Scherl; Robert J Desnick; Maria T Abreu; Hongyu Zhao; Gil Atzmon; Itsik Pe'er; Subra Kugathasan; Hakon Hakonarson; Jacob L McCauley; Todd Lencz; Ariel Darvasi; Vincent Plagnol; Mark S Silverberg; Aleixo M Muise; Steven R Brant; Mark J Daly; Anthony W Segal; Richard H Duerr; Miriam Merad; Dermot P B McGovern; Inga Peter; Judy H Cho Journal: Gastroenterology Date: 2016-07-01 Impact factor: 22.682